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Introduction: Huntington’s disease (HD) is an autosomal dominant disorder caused by an expanded CAG repeat
(greater than 38) on the short arm of chromosome 4, resulting in loss and dysfunction of neurons in the
neostriatum and cortex, leading to cognitive decline, motor dysfunction, and death, typically occurring 15 to
20 years after the onset of motor symptoms. Although an effective treatment for HD has remained elusive, current
studies using transplants of bone-marrow-derived mesenchymal stem cells provides considerable promise. This
study further investigates the efficacy of these transplants with a focus on comparing how passage number of these
cells may affect subsequent efficacy following transplantation.
Methods: In this study, mesenchymal stem cells isolated from the bone-marrow of mice (BM MSCs), were labeled
with Hoechst after low (3 to 8) or high (40 to 50) numbers of passages and then transplanted intrastriatally into
5-week-old R6/2 mice, which carries the N-terminal fragment of the human HD gene (145 to 155 repeats) and
rapidly develops symptoms analogous to the human form of the disease.
Results: It was observed that the transplanted cells survived and the R6/2 mice displayed significant behavioral and
morphological sparing compared to untreated R6/2 mice, with R6/2 mice receiving high passage BM MSCs
displaying fewer deficits than those receiving low-passage BM MSCs. These beneficial effects are likely due to
trophic support, as an increase in brain derived neurotrophic factor mRNA expression was observed in the striatum
following transplantation of BM MSCs.
Conclusion: The results from this study demonstrate that BM MSCs hold significant therapeutic value for HD, and
that the amount of time the cells are exposed to in vitro culture conditions can alter their efficacy.* Correspondence: dunba1g@cmich.edu
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Huntington’s disease (HD) is an autosomal dominant
disorder caused by an expanded and unstable CAG tri-
nucleotide repeat that results in a progressive degener-
ation of neurons, primarily in the putamen, caudate
nucleus, and cerebral cortex. The underlying pathology
of HD is initiated when the gene that codes for the hun-
tingtin (htt) protein, located on the short arm of
chromosome 4, contains an increased number of CAG
repeats [1]. HD in adults is characterized by cognitive
impairment and psychiatric disturbances, such as irrit-
ability, aggressiveness, and depression, which precede in-
voluntary motor disturbances [1,2], with death usually
occurring 15 to 20 years later.
The R6/2 mouse model of HD expresses the N-terminal
portion of human htt, containing a highly expanded glu-
tamine repeat (145 to 155). These mice develop progres-
sive neurological phenotypes resembling HD [3]. At birth,
R6/2 mice are indistinguishable from wild-type (WT) lit-
termates and develop normally until 6 to 8 weeks of age,
when they begin to express the HD phenotype, initially
consisting of neurological signs of stereotypical hind-limb
grooming, dyskinesia, irregular gait, and motor dysfunc-
tion [4,5]. The R6/2 model also displays significant re-
ductions in brain-derived neurotrophic factor (BDNF), a
protein necessary for striatal neuron survival that is re-
duced in HD patients [6,7]. Studies aimed at increasing
BDNF within the striatum have shown beneficial results
in transgenic animal models of HD, adding evidence to
the therapeutic role of BDNF [8-10].
Over the last several decades, stem cell transplantation
has gained significant attention as potential treatment
for neurodegenerative diseases, including HD, as patients
with HD have received clinical benefits from implants of
fetal/embryonic stem cells [11-13]. Despite some encour-
aging results, the use of fetal/embryonic cell sources for
therapeutic transplantation is still subject to logistical, im-
munological, and ethical limitations [12,14,15].
To avoid some of these complications, use of adult,
bone marrow (BM)-derived stem cells have gained consid-
erable interest. Cultured mesenchymal stem cells (MSCs)
are characterized by plastic adherence, rapid proliferation,
and multipotency [16]. Transplantation of BM MSCs into
the striatum of rodent models of HD has been shown to
reduce behavioral deficits [17] and provide neurotrophic
support (for a review, see [18]).
Given that MSCs are readily available and can provide
functional efficacy following transplantation, they hold
considerable promise as a source for an effective cell
therapy. However, in order to expand BM MSCs in suffi-
cient numbers for transplantation, in vitro passaging,
which has shown to alter the properties of the cells [19],
is necessary. Our previous work suggested that reducing
the number of cell passages may increase transplantsurvivability in rats and increase their efficacy in redu-
cing behavioral deficits in the 3-nitropropionic acid rat
model of HD [20].
The goals of the present experiment were to test the ef-
ficacy of BM MSCs in the R6/2 transgenic mouse model
of HD, and to determine whether increased passaging of
MSCs in vitro can alter functional outcomes following
transplantation. Behavioral and histological analyses were
performed to examine the efficacy of both low-passage
(passages 3 to 8) and high-passage (passages 40 to 50) BM
MSCs transplanted into the striata of R6/2 mice.
Methods
In vitro cell characterization
The extraction protocol for obtaining BM MSCs was
adapted from previously published procedures [10]. Briefly,
BM was aspirated from the fibula of adult (6-week-old
to 8-week-old) WT littermates of R6/2 transgenic mice
(C57/BL6 background; Jackson Laboratory, Bar Harbor,
ME, USA) using a 25 gauge syringe. The cells were then
suspended in 10 ml MSC medium (alpha modified Eagle’s
medium (Sigma, St Louis, MO, USA) with 10% fetal
bovine serum (Invitrogen, Carlsbad, CA, USA), 10%
horse serum (Invitrogen), and 5 mg/ml streptomycin
and 5 UI/ml penicillin (Sigma)). Following incubation
for 48 hours at 37°C, the medium was replaced with
fresh MSC medium to remove nonadherent cells.
When cells reached 85% confluency, the cells were
passaged. Briefly, the culture medium was aspirated,
0.25% trypsin/ethylenediaminetetraacetic acid solution
(Sigma) was added for 5 minutes to detach the cells, and
trypsin was then deactivated with 2 ml fetal bovine
serum. The trypsin/ethylenediaminetetraacetic acid solu-
tion and fetal bovine serum containing the cells was col-
lected and centrifuged at 1,500 rpm for 7 minutes at 4°C.
The supernatant was removed and the pellet was then sus-
pended, resuspended, counted, and replated at a density of
8,000 cells/cm2 in a new 75 cm2 flask (Phenix, Candler,
NC, USA) with fresh MSC media. At low passages, 85%
confluency of the MSCs was reached initially at every other
week and, subsequently, once each week. When growth
kinetics stabilized, around passage 10, MSCs reached
85% confluency twice per week.
At passage 6 (low passage) and at passage 50 (high
passage), the BMMSCs were analyzed using immunocyto-
chemistry. Briefly, BM MSCs were plated into six-well
plates containing poly-L-ornithine coated glass coverslips
(25 mm #1; Thermo Fisher Scientific Inc, Waltham, MA,
USA) and cultured in MSC medium. At 80% confluency,
the cells were fixed with 4% paraformaldehyde in 0.1 M
phosphate-buffered saline (PBS) at 4°C for 10 minutes. To
block nonspecific binding sites, the coverslips were incu-
bated for 1 hour at room temperature in PBS with 0.1%
Triton-X (Sigma) and 10% normal goat serum (Sigma).
Table 1 Primer sequences used in quantitative RT-PCR
analysis
Primer Sequence
GAPDH forward AAG AGA GGC CCT ATC CCA A
GAPDH reverse CAG CGA ACT TTA TTG ATG GTA
BDNF forward GAA GAG CTG CTG GAT GAG GAC
BDNF reverse TTC AGT TGG CCT TTT GAT ACC
TrkB forward CTC AAG TTG GCG AGA CAT TCC A
TrkB reverse AAT CCA GGC ACT TCC TCG TTC
NGF forward TAG CGT AAT GTC CAT GTT GT
NGF reverse CCC ACA CAC TGA CAC TGT CA
TNFα forward GTT CGG ATC CCA CTG TGA CT
TNFα reverse GTC CCC AGA GCC AAT GAC TA
BDNF, brain-derived neurotrophic factor; GAPDH, glyceraldehyde 3-phosphate
dehydrogenase; NGF, nerve growth factor; TNFα, tumor necrosis factor alpha;
TrkB, tyrosine receptor kinase type 2.
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primary antibodies overnight at 4°C. Primary anti-
bodies included CD45 (1/500; Abcam Cambridge, MA,
USA) and SCA1 (1/500; Abcam). After 24 hours, the
coverslips were then rinsed and incubated for 1 hour at
room temperature with the appropriately conjugated
secondary antibodies. The secondary antibodies included
AlexaFluor488 and AlexaFluor594 (1/300; Invitrogen).
The coverslips were then rinsed and incubated in Hoechst
33358 (1/1,000; Thermo Scientific Thermo Fisher Scien-
tific Inc, Waltham, MA, USA) for 5 minutes at room
temperature to visualize cell DNA and then mounted onto
glass slides using Fluoromount (Sigma). Slides were
imaged at 20x using a Zeiss Axiovert 200 M inverted
fluorescent microscope (Zeiss, Thornwood, NY, USA).
The low-passage and high-passage BM MSCs were an-
alyzed by flow cytometry at passages 8 and 45, respect-
ively, following protocols published previously [21].
Briefly, 200,000 to 300,000 cells were plated into each
well of a round-bottom 96-well plate following a pas-
sage. The cells were rinsed in 0.1 M PBS containing 1%
bovine serum albumin (Sigma) and 0.1% azide (Sigma)
and were centrifuged at 2,500 rpm for 1 minute at 4°C.
The cells were then resuspended in 30 μl primary anti-
bodies for 1 hour at 4°C. The primary antibodies and di-
lutions were described above for immunocytochemistry
with the addition of the stage-specific embryonic antigen
SSEA4 (a marker of stem cells, 1/500; Abcam), major
histocompatibility complex (MHC) class I (a receptor for
T-cell identification, 1/500; Abcam), and MHC class II
(a marker of antigen-presenting cells and lymphocytes).
The cells were then rinsed twice and incubated in the
secondary antibody,AlexaFluor488, (1/300; Invitrogen,
Grand Island, NY, USA) for 1 hour at 4°C. The cells were
then rinsed twice and fixed using 4% paraformaldehyde
for 10 minutes on ice. The cells were then rinsed and
stored at 4°C until analysis was performed using the LSR
II (BD Bioscience, San Jose, CA, USA).
Cell cultures were also analyzed for BDNF mRNA ex-
pression. Briefly, two million cells were isolated following
passaging and stored at −80°C in 200 μl Trizol overnight.
RNA isolation was then performed using a Qiagen RNeasy
system (Qiagen, Gaithersburg, MD, USA). All procedures
followed the manufacturers’ guidelines. The purified RNA
was analyzed using a NanoDrop2000 spectrophotometer
(ThermoScientific Thermo Fisher Scientific Inc, Waltham,
MA, USA), and was then stored at −20°C.
A QuantiTect Reverse Transcription Kit (Qiagen) was
used for cDNA synthesis following the manufacturers’
guidelines. Primers used for quantitative PCR were BDNF,
tyrosine receptor kinase type 2 (TrkB), tumor necrosis fac-
tor alpha (TNFα) and nerve growth factor (NGF). All values
were normalized to the housekeeping gene glyceraldehyde
3-phosphate dehydrogenase and the fold increase wascalculated from control cDNA isolated from mouse tail-
tip fibroblasts. Sequences are located in Table 1.
Animals
All procedures mentioned were reviewed and accepted
under the guidelines of the Institutional Animal Care
and Use Committee of Central Michigan University.
Male and female R6/2 and WT mice were housed at
22°C under a 12-hour light/12-hour dark reverse light
cycle with ad libitum access to food and water. The
mice were genotyped at 3 weeks of age by PCR and sep-
arated into the following four groups balanced by gender
and genotype: sham-operated (injection into the stri-
atum of Hanks balanced salt solution; Gibco, Thermo
Fisher Scientific Inc, Waltham, MA, USA) WT mice
(WT group; n = 19); sham-operated R6/2 mice (R6/2
group; n = 10); R6/2 mice transplanted with low-passage
BM MSCs (R6/2 BM Low group; n = 7); and R6/2 mice
transplanted with high-passage BM MSCs (R6/2 BM
High group; n = 10). Following group assignment, the
experimenters were blinded to the group identity until
the conclusion of the experiment.
Bone marrow mesenchymal stem cell transplantation
At 5 weeks of age, mice were anesthetized with isoflur-
ane gas and oxygen. The head of each mouse was shaved
and cleaned using chlorhexadine (Molnlycke Healthcare
Norcross, Georgia, USA). Prior to placing the mouse in the
stereotaxic device, 2% lidocaine gel (Hi-tech Pharmacal
was just acquired by Akorn, Lake Forest, IL, USA) was
placed on the tip of the ear bars. Anesthesia was maintained
with isoflurane gas and oxygen for the duration of the sur-
gery. A midline incision was made on the scalp and the skin
was retracted, exposing bregma. Two burr holes (0.5 mm)
were placed directly over the neostriatum (coordinates rela-
tive to bregma: anterior +0.5 mm; lateral ± 1.75 mm; tooth
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low passage (passages 3 to 8) or high passage (passages 40
to 50) were pre-labeled with Hoechst 33358 (5 μg/ml;
Sigma) and resuspended at a density of 200,000 cells/μl in
Hanks balanced salt solution. The cells were loaded into a
10 μl Hamilton microsyringe and bilaterally transplanted
(2.5 mm ventral to dura) at a constant rate of 0.33 μl/
minute for 3 minutes. Following the first injection, the
syringe was left in place for 3 minutes, raised 1 mm, and
injected a second time (two injections of 200,000 cells).
After a second 3-minute wait period, the microsyringe was
withdrawn at a steady rate over a 3-minute period. The
same procedure was then followed on the opposite hemi-
sphere, the burr holes were sealed with bone wax, and the
wound was closed using sterile wound clips (7 mm). The
mice were placed in a recovery cage until fully mobile, at
which point they were returned to their home cage.
Behavioral tests
All mice were tested for baseline behavior at 5 weeks of
age, prior to cell transplantation. Mice underwent 6 weeks
of testing on all behavioral tasks, beginning the week fol-
lowing surgery; except for the Morris water maze (MWM)
task, for which testing began 2 weeks following surgery
and lasted 5 weeks.
Rotarod test
The rotarod (SDI Rotor-Rod; San Diego Instruments
San Diego, CA, USA) was used to assess motor coordin-
ation. The mice were required to maintain balance on a
3 cm diameter rotating rod for 60 seconds. The rod
rotated at a constant speed of 10 rpm and each mouse
was given three trials per day. If the mice were incapable
of remaining on the rotarod for the full 60 seconds, they
fell onto a foam pad placed below the apparatus.
Clasping
The mice also had their limb-clasping response recorded.
Procedures followed previously published protocols [8].
Briefly, the mice were suspended by their tails from a
height of 50 cm for 30 seconds, and a limb-clasping re-
sponse was defined as the withdrawal of any limb to the
torso for more than 1 second. Each testing session con-
sisted of three trials with a clasping score ranging from 0
to 4, with 0 representing the absence of clasping, 1 repre-
senting a withdrawal of any single limb, 2 representing the
withdrawal of any two limbs, 3 representing the with-
drawal of any three limbs, and 4 representing the with-
drawal of all four limbs. The limb-clasping response scores
were averaged for each testing session for each animal.
Morris water maze
An adapted MWM was used to test cognitive function
through spatial memory [22]. Briefly, the MWM is atank of 142 cm diameter filled with opaque water
(30.5 cm deep water mixed with nontoxic white paint).
A 14-cm diameter platform was placed 1 cm below the
surface of the water. Extra-maze visual cues included the
testing room door and window on the wall of the south
starting location. Prior to baseline testing, each mouse
was given a cued trial, where the platform was placed in
the center of the MWM with an attached visible flag as
a cue. The mice were given four training trials from four
starting locations (north, south, east, and west) to
acclimatize the mice to the water and the escape para-
digm, as well as assessing their visual acuity and swim-
ming ability. During each testing week, the mice were
placed in the water facing the south location and the
hidden platform was subsequently altered each testing
day between the northwest and northeast quadrants,
with the platform in the center of the quadrant. During
baseline, and on subsequent testing days, the mice were
given five trials to find the hidden platform. Following a
successful trial, the mice were left on the platform for
5 seconds, removed from the tank, dried, and given a
45 second inter-trial interval. Mice who did not locate
the hidden platform within 60 seconds were guided by
hand to the platform and allowed to rest on the platform
for 5 seconds. The swim speed, distance traveled, and la-
tency to find the hidden platform was measured using
Viewpoint VideoTrack version 1.75 (Videotrack; View
Point Life Science, Montréal, QC, Canada). However,
given the progressive motoric deficits that emerge in the
R6/2 mice, the dependent measure used in this study
was the percentage of correct responses. Each trial was
scored as correct if the mouse was able to find the hid-
den platform in less than 60 seconds and the percent of
correct responses was calculated at the end of each test-
ing session:
Correct responses %ð Þ ¼ ðnumber of correct trials=number of total trialsÞ
 100
Histological analysis
At the conclusion of behavioral testing, when mice were
12.5 weeks old, one-half of the animals from each group
were deeply anesthetized with an overdose of sodium
pentobarbital (intraperitoneally), and transcardially per-
fused with 0.1 M PBS, followed by 4% paraformaldehyde
(diluted in 0.1 M PBS at pH 7.4) to fix the brains.
The brains were then rapidly removed, suspended in
4% paraformaldehyde for 24 hours at 4°C, and then
transferred to 30% sucrose in 0.1 M PBS for 48 hours
at 4°C. The brains were then flash frozen using
methylbutane (Sigma) and were stored at −80°C until
they were processed.
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5000; Leica, Buffalo Grove, IL, USA) at 30 μm, labeled
using previously established free-floating fluorescent stain-
ing protocols [20] and mounted on positive-charged micro-
scope slides (Globe Scientific Inc., Paramus, NJ, USA). For
immunohistochemical analysis, the tissue was labeled with
antibodies for neuronal nuclei (mouse NeuN, 1/500;
Abcam) and glial fibrillary acid protein (rabbit GFAP,
1/500; Abcam). The tissue was first blocked using 10%
normal goat serum in PBS with 0.1% Triton-X for 45 mi-
nutes at room temperature. The tissue was then transferred
to a well containing the primary antibodies and stored at 4°
C overnight. The following day, the tissue was rinsed three
times in PBS with 0.1% Triton-X and transferred to a
well containing the appropriately conjugated secondary
antibodies for 1 hour at room temperature. Secondary
antibodies consisted of anti-rabbit AlexaFluor488 and
anti-mouse AlexaFluor594 (1/300; Invitrogen).
Cytochrome oxidase (CYO) histology was used to de-
termine the extent of metabolically active tissue, and
these same sections were used for subsequent morpho-
logical analysis. Briefly, the tissue was submersed in a so-
lution of 800 mg sucrose, 4 mg cytochrome C, and 1 mg
diaminobenzadine dissolved in 20 ml phosphate buffer
for 4 hours at room temperature on an agitator. The tis-
sue was then transferred to deionized water, mounted
onto positively charged glass slides, and coverslipped
using Depex (Electron Microscopy, Hatfield, PA, USA).
Image acquisition and analysis
Images of the fluorescent labels were captured using a
Zeiss Axiovert 200 M inverted fluorescent microscope
with optical dissectors at 20× magnification. CYO labeled
tissue was scanned using Nikon ScanPro (Nikon, Melville,
NY, USA). Images were captured from five levels, centered
at 0.5 mm anterior to the bregma (the transplant site) with
two additional sections anterior and posterior to the
transplant site, approximately 200 μm apart.
All images were analyzed using ImageJ (National Insti-
tutes of Health, Bethesda, MD, USA). The average intensity
of the fluorescent label, the counts of positively labeled
cells, as well as the percentage of colocalization between
the transplanted MSCs and NeuN or GFAP were analyzed
between all groups. The average intensity of the fluorescent
label, the number of labeled cells, and the percentage of
cells that were co-labeled for both MSCs and either NeuN
or GFAP were analyzed from samples of all transplant
groups. Methods for rare-event stereology were modified
from previously published protocols [23,24]. Briefly, cell
counts were made from the dorsal striatum within each
section. Cells were counted as positive cells if they showed:
antibody immunoreactivity within the cell body; the nucleus
of that cell was within the counting frame without touching
the exclusion lines; and the nucleus of that cell was in focus.For cell counts, the average number of cells per section was
calculated.
Densitometric measures of CYO and GFAP were taken
from the striatum and the average intensities were nor-
malized to the corpus callosum of each section. For the
total brain area, sections were traced using ImageJ and
the total area was calculated.
RNA isolation of transplanted brain
Mice that were not used for immunohistological analysis
were killed via cervical dislocation when the mice were
12.5 weeks old, and striata of these mice were isolated,
flash-frozen with liquid nitrogen, and stored at −80°C.
RNA isolation was performed using a Qiagen All-Prep
system following the manufacturer’s guidelines. Briefly,
striatal tissue was homogenized using a lysis buffer and
transferred to an All-Prep spin column and centrifuged
at 9500 rpm for 1 minute. Purified RNA was collected in
the collection tube and analyzed using a NanoDrop2000
spectrophotometer (ThermoScientific), and was stored at
−20°C until used for cDNA synthesis. A QuantiTect
Reverse Transcription Kit (Qiagen) was used for cDNA syn-
thesis following the manufacturer’s guidelines. The cDNA
was stored at −20°C until use in quantitative PCR experi-
ments. The primers used for gene expression were BDNF,
NGF, TrkB, and TNFα. All values were normalized to
the housekeeping gene, glyceraldehyde 3-phosphate
dehydrogenase, and the fold increase was calculated from
control cDNA isolated from mouse brain homogenate.
The sequences for each primer are presented in Table 1.
Statistical analysis
All statistical analyses were performed using SPSS v16 (IBM
SPSS Statistics, Armonk, NY, USA) with an alpha level
equal to 0.05. Assays between low-passage and high-passage
BM MSCs in vitro were analyzed using an independent-
samples t test. All behavioral data were analyzed using a
repeated-measures analysis of variance (ANOVA), to meas-
ure changes between genotypes and treatments across
weeks. Histological data were analyzed using a one-way
ANOVA. When appropriate, a Tukey’s honestly significant
difference (HSD) test was performed for post hoc analyses.
Results
In vitro cell characterization
Both low-passage and high-passage BM MSCs showed
positive expression of SCA1, a marker of mouse MSCs,
without expressing CD45, a marker of hematopoietic
stem cells (Figure 1). Flow cytometry analysis (Table 2)
revealed that low-passage BM MSCs displayed 14.3%
positive expression of SCA1, while high-passage BM
MSCs displayed 74.4% positive expression of SCA1, indi-
cating that SCA1 changes over passages. With respect to
CD45, analyses of the flow cytometry data revealed a
Figure 1 Immunocytochemistry of low-passage and high-passage bone marrow mesenchymal stem cells . (A) Low-passage bone marrow
mesenchymal stem cells (BM MSCs) and (B) high-passage BM MSCs displayed typical MSC morphology, expressed the mesenchymal stem cell
marker SCA1, and were negative for the hematopoietic stem cell marker CD45. Scale bar represents 100 μm.
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high passage, respectively. In terms of SSEA4, a marker of
stem cells, flow cytometry data indicated an increase from
2.2% in low-passage BM MSCs to 95.5% in high-passage
BM MSCs. MHC class I expression remained relatively
stable between low-passage and high-passage BM MSCs,
at 3.7% and 4.0%, respectively. MHC class II expression
also remained relatively stable between low-passage and
high-passage BM MSCs, at 2.7% and 4.4%, respectively.
These data indicate that either a selection process is taking
place over passages, with SCA1+/CD45– cells proliferating
at a higher rate, or that prolonged exposure to culture con-
ditions causes expression levels to change. In either case,
these data suggest that high-passage mouse BM MSCs
may prove to be more suitable for transplantation studies.
An independent t test of BDNF gene expression re-
vealed a significant difference between low-passaged and
high-passaged BM MSCs (t(4) = 9.120, P = 0.001), with
high passages displaying a significantly higher expression
of BDNF mRNA – suggesting that high-passage BM
MSCs may prove to be more effective following intra-
striatal transplantation, due to greater mRNA expression
of the pro-neuron survival trophic factor (Figure 2).Table 2 Flow cytometry results of low-passage and
high-passage bone marrow mesenchymal stem cells




MHC class I 3.7 4.0
MHC class II 2.7 4.4
An increase in the number of cells positively expressing SCA1 was observed as
the passage number increased. An increase in the stem cell marker SSEA4 was
also observed as the cell passage increased. Expression levels of CD45, MHC
class I, and MHC class II remained relatively stable as the passage number
increased. MHC, major histocompatibility complex.Behavioral results
In the R6/2 model of HD, clear motoric deficits, tested
on the rotarod, become apparent at 6 weeks of age. A
repeated-measures ANOVA revealed a significant inter-
action between weeks and group (F(18,174) = 2.247, P =
0.004) as well as a significant between-group difference
for the latency to fall during the rotarod task (F(3,29) =
12.092, P = 0.001; Figure 3). A Tukey’s HSD post hoc
analysis revealed significant motoric deficits between
R6/2 and WT mice at each time point following baseline
testing. Mice transplanted with low-passage BM MSCs
displayed only modest benefits in their performance on
the rotarod task, with deficits delayed by 1 week, relative
to nontransplanted R6/2 controls.Figure 2 In vitro quantitative RT-PCR of brain-derived neurotrophic
factor mRNA expression of bone marrow mesenchymal stem cells.
A significant increase in mRNA levels of brain-derived neurotrophic factor
(BDNF) was observed in the high-passaged bone marrow mesenchymal
stem cells (BM MSCs) compared with low-passaged BM MSCs. †Significant
from high-passage BM MSCs; tail-tip fibroblasts (TTF) are control cDNA
isolated from mice. Bar graph represents mean value; error bars represent
standard error of the mean.
Figure 3 Assessment of motor coordination in R6/2 mice
following bone marrow mesenchymal stem cell
transplantation. A significant decline in motor coordination was
observed in untreated R6/2 mice when compared with wild-type
(WT) mice. The R6/2 mice who received transplantation of high-
passage bone marrow mesenchymal stem cells (BM MSCs) displayed
significantly longer latencies to fall compared with untreated R6/2
mice starting at 7 weeks of age and continuing throughout the
study. *Significant from WT; #significant from R6/2; †significant from
high-passage BM MSCs. Data points on line graph represent mean
value; error bars represent standard error of the mean.
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high-passage BM MSCs, the latency to fall from the
rotarod was comparable with WT mice starting at base-
line (when the mice were 5 weeks old) and continuing
until the animals were 10 weeks old. Rotarod perform-
ance of mice with high-passage BM MSC transplants
were statistically different from nontransplanted R6/2Figure 4 Assessment of spatial memory in R6/2 mice following bone
mice displayed significant impairment in spatial memory at 5, 8, 9, 10, and
receiving either low-passage or high-passage bone marrow mesenchymal
memory at 8 and 9 weeks of age. *Significant from WT; #significant from R
mean value; error bars represent standard error of the mean.mice, beginning at 7 weeks of age, with this trend con-
tinuing throughout the duration of the study. A signifi-
cant difference on the rotarod task was also observed
between high-passage BM MSC and low-passage BM
MSC when the mice were 7 weeks old. Although high-
passage BM MSC transplanted mice eventually showed a
decline in motor coordination on the rotarod, they still
had significantly longer latencies to fall off the rotarod
than untreated R6/2 mice, suggesting behavioral sparing
occurred, even at the late stages of the progressive HD-
like deficits.
Analysis of cognition through MWM testing revealed
significant spatial learning deficits in the R6/2 mice,
appearing between 5 and 7 weeks of age. A repeated-
measures ANOVA revealed significant differences be-
tween groups for the percentage of correctly locating
the hidden platform (F(3,33) = 13.143, P = 0.001) and
a significant interaction between time and group
(F(15,165) = 3.014, P = 0.001; Figure 4). A Tukey’s HSD
post hoc analysis revealed significant differences be-
tween R6/2 and WT mice during the baseline testing
period, as well as significant differences when the mice
were 8, 9, 10, and 11 weeks old.
For mice that received transplantation of BM MSCs,
an intermediate effect in cognitive performance was ob-
served when the mice were 8 and 9 weeks old, when
they had a significantly higher percentage of correct re-
sponses than untreated R6/2 mice but still a significantly
lower probability to find the hidden platform than WT
mice. However, at 9 and 10 weeks of age, both transplant
groups showed declines in cognitive performance to the
untreated R6/2 level. These data indicate that, while amarrow mesenchymal stem cell transplantation. Untreated R6/2
11 weeks of age when compared with wild-type (WT) mice. Mice
stem cells (BM MSCs) displayed an intermediate sparing of spatial
6/2; †significant from high-passage BM MSCs. Bar graph represents
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transplantation of either low-passage or high-passage
BM MSCs, these mice display similar cognitive dysfunc-
tion in the later stages of the HD-like progression of
cognitive deficits.
The limb-clasping response is a reliable behavioral
phenotype observed in many transgenic animals, and
may be related to cortical dysfunction in this mouse
model of HD [8,22,25]. A repeated-measures ANOVA
revealed main effect of group in the limb-clasping re-
sponse task (F(3,37) = 20.204, P = 0.001), and a significant
interaction between week and group (F(18,222) = 9.740,
P = 0.001; Figure 5).
Confirming this phenotypic behavior, Tukey’s HSD
post hoc analysis revealed significant differences between
R6/2 and WT mice beginning at 8 weeks of age and
continuing for the duration of the study. A Tukey’s post
hoc analysis also revealed that R6/2 mice transplanted
with high-passage BM MSCs showed a delay in onset of
limb clasping until 10 weeks of age, at which point these
animals also showed significantly fewer limb clasps com-
pared with R6/2 mice transplanted with low-passage BM
MSCs. Significant differences were also observed be-
tween the high-passage BM MSC group and untreated
R6/2 mice starting at 9 weeks of age. Interestingly, R6/2
mice receiving transplants of low-passage BM MSCs dis-
played significantly more limbs clasped, compared with
WT mice, during all testing weeks, whereas untreated
R6/2 mice did not start showing significantly moreFigure 5 Limb-clasping response of R6/2 mice following bone marrow
significantly more limb-clasping responses than wild-type (WT) mice startin
of the study. R6/2 mice that received transplantations of high-passage bon
limb-clasping responses than untreated R6/2 mice for the duration of the s
R6/2; †significant from high-passage BM MSCs. Data points on line graph reclasping behavior than WT mice until the mice were
8 weeks old.
Histological results
Six weeks following transplantation, when mice were
12.5 weeks old, their brains were extracted, preserved,
and analyzed for possible morphological changes, levels
of CYO labeling (as a measure of mitochondrial integ-
rity), as well as transplant survival and levels of immune
response to the transplanted cells. Scans from five levels
of CYO-stained tissue were outlined, and total area of
the brain was analyzed for each animal (Figure 6A). A
one-way ANOVA revealed significant between-group
differences in the area of the whole brain from the sec-
tions analyzed (F(3,105) = 3.209, P = 0.026). A Tukey’s
HSD post hoc analysis revealed that total brain area in
untreated R6/2 mice was significantly smaller than in
WT animals, suggesting general brain atrophy. This
brain atrophy was not observed in R6/2 mice trans-
planted with low-passage or high-passage BM MSCs, as
both groups were not significantly different from the
WT group (Figure 6B).
Optical densitometric analysis of metabolically active
tissue in the striatum revealed a between-group differ-
ence (F(3,105) = 5.896, P = 0.002), with untreated R6/2
mice having less density of CYO labeling in the striatum,
when compared with WT mice. Mice transplanted with
low-passage MSCs were not significantly different from
either WT or untreated R6/2 mice. Importantly, themesenchymal stem cell transplantation. Untreated R6/2 mice had
g at 8 weeks of age, with this impairment continuing for the duration
e marrow mesenchymal stem cells (BM MSCs) had significantly fewer
tudy, starting at 9 weeks of age. *Significant from WT; #significant from
present mean value; error bars represent standard error of the mean.
Figure 6 Measures of brain area and evidence of integrity of the metabolic tissue in the striata of mice receiving bone marrow
mesenchymal stem cell transplantations. (A) Gross morphology of the brain near the area of transplantation can be visualized with cytochrome
oxidase (CYO) labeling. (B) Untreated R6/2 mice had a significant decrease in total brain area (outlined in solid black) when compared with WT mice.
Optical densitometric measures of CYO in the labeled tissue of the striata (outlined in dashed line) revealed significantly less metabolically active area
in untreated R6/2 mice when compared with wild-type (WT) mice at the time of necropsy. (C) R6/2 mice that received transplantation of high-passage
bone marrow mesenchymal stem cells (BM MSCs) had significantly higher levels of CYO labeling in the striata than did untreated R6/2 mice.
*Significant from WT; #significant from R6/2. Data points on line graph represent mean value; error bars represent standard error of the mean.
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R6/2 mice transplanted with high-passage BM MSCs
was indistinguishable from those levels observed in WT
mice (Figure 6C). These data suggest that transplant-
ation of either low-passage or high-passage BM MSCs
can prevent the loss of metabolically active tissue and
that transplantation of high-passage significantly reduces
the level of metabolic loss when compared with un-
treated R6/2 mice.
Analysis of the number of Hoechst-labeled BM MSCs
in the striatum at 6 weeks following transplantation re-
vealed no significant differences between low-passage
and high-passage groups (t(43) = 1.372, P = 0.233), dem-
onstrating that both low-passage and high-passage BM
MSCs were capable of surviving in the brain (Figure 7B).
To confirm that the Hoechst label was not leaching from
the BM MSCs, dead BM MSCs labeled with Hoechst
were transplanted into the brain of a normal mouse and
there were no positively-labeled cells at 6 weeks follow-
ing transplantation, confirming that the fluorescent cell
linker was not transferred to the host (data not shown).
Analysis of images taken from fluorescent microscopy
revealed that transplanted cells did not colocalize with
immunohistochemistry-labeled tissue for mature neurons
(NeuN) and astrocytes (GFAP; Figure 7A), suggesting that
BM MSCs did not differentiate into tissue of a neuronal
lineage. Optical densitometry analysis of GFAP-labeledtissue from the areas around the transplant site revealed
no significant differences between groups (F(3,88) =
0.440, P = 0.725; Figure 7C).
mRNA expression
As neurotrophic factors, such as BDNF, play an important
role in the pathology of HD, mRNA was isolated from the
striatum of mice 6 weeks following transplantation. RT-
PCR analysis of BDNF expression revealed a significant
main effect of group (F(3,15) = 4.134, P = 0.032; Figure 8A).
A Tukey’s HSD post hoc analysis revealed that untreated
R6/2 mice had a significant reduction in BDNF expression
compared with WT mice. Both BM MSC transplant
groups had significantly higher expression of BDNF com-
pared with untreated R6/2 mice. Analysis of expression
levels of the BDNF receptor TrkB revealed no significant
differences between groups (F(3,15) = 1.895, P = 0.184;
Figure 8B), although a strong trend was observed be-
tween WT and R6/2 mice. Similar to TrkB, a one-way
ANOVA revealed no significant between-group differ-
ences in gene expression of NGF in the tissue dissected
from the striata (F(3,13) = 2.232, P = 0.147), although a
trend towards reduced NGF expression was observed in
the R6/2 mice compared with WT mice (Figure 8C).
Analysis of the proinflammatory gene TNFα revealed no
significant between-group differences in gene expression
(F(3,15) = 2.664, P = 0.095; Figure 8D).
Figure 7 Immunohistochemical analyses of the transplanted bone marrow mesenchymal stem cells. (A) No neuronal or glial
differentiation was observed from the transplanted bone marrow mesenchymal stem cells (BM MSCs) as seen by the lack of colocalization
between the BM MSCs (blue) with neuronal nuclei (NeuN; red) or glial fibrillary acid protein (GFAP; green), respectively in either low-passage
(left panel) or high-passage (right panel) BM MSC.(B) No significant differences were observed in the amount of surviving BM MSCs between
low-passage and high-passage BM MSCs. (C) Also, no significant differences were observed between all groups in densitometric measures of
GFAP around the transplant site.
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This study yielded four main findings: transplantation of
BM MSCs into the striata of R6/2 mice significantly de-
lays the progressive motor and cognitive dysfunction as-
sociated with this model; the beneficial effects of these
cells is dependent on the number of times they have
been passaged; transplantation of these cells can pre-
serve anatomical features in the R6/2 brain in the ab-
sence of evidence for neuronal differentiation; and
transplantation of BM MSCs can prevent/restore the de-
creased expression of BDNF in the striata of R6/2 mice.
The data from this study corroborate earlier findings
from our laboratory demonstrating behavioral and neuro-
pathological sparing in an HD model following transplant-
ation of BM MSCs [8,10,17,23]. This study shows that BM
MSCs were capable of slowing the progressive decline in
motor and cognitive performance in a highly aggressive
mouse model of HD. The current results support our pre-
vious work indicating that autologous BM transplants into
the striata of rats given intra-striatal injections of quinoli-
nic acid (QA) can reduce cognitive deficits in the radial-
arm water-maze task [17]. The precise mechanism
whereby this cognitive deficit is ameliorated remainsunknown, but may involve the preservation of striatal cells
known to be involved with place field properties [26]. The
efficacy of MSCs in treating HD-like deficits has also been
observed in the QA rat model of HD, using BM MSCs
[27]. Other sources of MSCs, such as adipose-derived
MSCs/stromal cells, reduced the motor deficits in the R6/
2 mouse model [28]. While the suggested mechanisms of
action of transplanted MSCs being reported in these stud-
ies are different, the overall results of these studies provide
converging evidence for the potential use of MSCs as a
therapy for HD.
In the current study, we observed in vitro changes in
gene expression of BDNF, as well as an increase in ex-
pression of cell surface proteins, SSEA4 and Sca1, as a
result of passaging. Although both low-passage and
high-passage MSCs are derived from the same source, it
is possible that the process of passaging has selected two
separate populations with differential expression of these
genes, an effect we have observed previously in MSCs
isolated from the umbilical cord [23]. Contrary to what
was observed in our previous study using rat BM MSCs,
it is apparent that, in this model, mouse BM MSCs are
more therapeutically beneficial after extended periods in
Figure 8 In vivo quantitative RT-PCR of BDNF, TrkB, NGF, and TNFα mRNA expression (fold increase over tail-tip fibroblast) following
transplantation of bone marrow mesenchymal stem cells. (A) Untreated R6/2 mice had significantly lower expression of brain-derived
neurotrophic factor (BDNF) than wild-type (WT) mice, R6/2 mice receiving low-passage bone marrow mesenchymal stem cells (BM MSCs), and
R6/2 mice receiving high-passage BM MSCs. No significant differences were observed in the expression levels of (B) tyrosine receptor kinase type
2 (TrkB), (C) nerve growth factor (NGF), or (D) tumor necrosis factor alpha (TNFα) between groups. *Significant from WT; #significant from R6/2.
Data points on line graph represent mean value; error bars represent standard error of the mean. TTF, tail-tip fibroblast.
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[6], we are suggesting that the high-passage mouse BM
MSCs were better suited towards delaying the onset of
both motor and cognitive deficits in an aggressive mouse
model of HD due to significantly higher mRNA expres-
sion of BDNF in vitro.
Previous results in our laboratory have shown that
MSCs decreased their immune response following striatal
transplantation [20]. Although the differences in behav-
ioral outcome between transplantation of low-passage and
high-passage BM MSCs may have been due to differences
in the immunomodulatory effects of these cells, we do not
think this is likely, given that the cells did not significantly
modulate astrocyte activation following intrastriatal trans-
plantation. For example, expression of a proinflammatory
gene (TNFα) and densitometric analysis for immunola-
beled reactive astrocytes (GFAP) within striatal tissue did
not reveal significant differences between groups. Given
the lack of increased inflammation within the R6/2
brain, relative to WT brains, as well as amelioration of
behavioral deficits following transplantation of MSCs,
we hypothesize that the observed benefits are not a re-
sult of immunomodulation.Contrary to late-stage human HD, late-stage R6/2
mice do not have massive loss of striatal neurons. How-
ever, significant decreases are observed in the levels of
metabolically active tissue within the striatum, which is
suggestive of striatal dysfunction [29]. This study was
able to demonstrate a neuroprotective effect of trans-
planted BM MSCs. These results are similar to what has
been observed following MSC transplantation into the
N171-82Q mouse model of HD [30], although few sur-
viving transplanted cells were reported in this study. In
QA lesion models, a reduction of striatal atrophy has
been observed following MSC transplantation, with a
small number of surviving cells observed at 16 weeks
after transplantation [31,32].
The ability of MSCs to survive following transplant-
ation into the brain is currently being studied in several
laboratories, with widely varying results being reported.
In the current study, no significant difference in the
number of surviving MSCs was found between high-
passage and low-passage groups at 6 weeks following
transplantation. This is similar to other studies that have
observed robust MSC survival following transplantation
in a QA rat [33,34]. We have recently reported that
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decreases the general activity of the hypoimmunogenic
dendritic cells, macrophages, and T lymphocytes, which
translated into reducing the probability of MSC rejection
[20]. Because cytogenic analyses were not performed on
MSCs in the current study, the possibility that chromo-
somal abnormalities may have influenced the present re-
sults cannot be ruled out. However, despite findings that
murine BM MSCs are highly susceptible to chromo-
somal abnormalities as early as 10 days in culture
[19,35,36], tumor formation following MSC transplant-
ation into the brains of rodent HD models has not been
observed.
As the numbers of surviving BM MSCs in the present
study were not different between the two different pas-
sage groups after transplantation, the differences ob-
served in behavioral and histological sparing between
mice receiving low-passaged or high-passaged MSCs
were not due solely to the number of MSCs in the brain.
Further, as BM MSCs were not seen to differentiate into
neuronal-lineage cells, replacement of lost or damaged
cells is not responsible for the behavioral and histo-
logical results. Other mechanisms such as secretion of
trophic factors, like BDNF, therefore need to be identi-
fied to account for the therapeutic effects of the trans-
planted MSCs.
It has been found that patients with symptomatic HD
with lower serum concentration levels of BDNF have
significantly impaired motor and cognitive perfor-
mances, relative to individuals with normal BDNF levels
[37,38]. It is also shown that BDNF is very important for
survival and differentiation of striatal neurons, and that
lower BDNF may be a causative factor in the deterior-
ation of specific neuronal populations that is observed in
HD [6].
In the current study, transplantation of BM MSCs in
the striata of R6/2 mice significantly restored BDNF ex-
pression levels. As the loss of BNDF mRNA expression
has been shown to be significantly reduced in 6-week-
old R6/2 mice [22], we postulate that the secretion of
BDNF from transplanted BM MSCs when R6/2 mice
were 5 weeks of age prevented this age-dependent loss
of BDNF mRNA expression in these R6/2 mice. Al-
though we did not directly measure BDNF protein levels
in this study, we have previously observed an increase in
BDNF immunolabeling within the striatum following
transplantation of MSCs [20], which supports our con-
tention that BDNF upregulation may play a major role
in the observed behavioral sparing in the present study.
Our findings confirm those of Jiang and colleagues,
who observed an upregulation of BDNF following MSC
transplantation in a toxic lesion model of HD [39]. The
capacity of MSCs to secrete growth factors and other
neuroprotective factors in vitro and in vivo followingtransplantation has been well documented [8,40,41].
However, based on the current evidence, we are unable
to determine whether the BDNF is secreted from the
transplanted cells, or whether it is upregulated in brain
tissue as a result of BM MSC transplantation. Testing
these hypotheses has become a focus of future studies in
our laboratory.
While our study suggests that BDNF plays a critical
role in the progression of HD symptoms and may be the
main mechanism behind the behavior and neuropatho-
logical sparing, other neurotrophic factors are critical for
disease progression as well. It has been shown that viral
delivery of glial-derived neurotrophic factor can amelior-
ate accelerod deficits and reduce hind-limb clasping in
the N171-Q82 mouse model of HD, similar to our find-
ings in the R6/2 model [42]. Clearly, more work is
needed to delineate the relative contribution of the sun-
dry putative factors that may underlie the functional
benefits exerted by the transplanted MSCs.
Our study suggests that high-passage mouse BM
MSCs are more suitable for transplantation in the R6/2
model. It is important to note, however, that this is likely
to be different for transplantation of rat or human MSCs
[20,43-46]. These conflicting results between mouse, rat,
and human MSCs add to an increasing body of evidence
that different populations of MSCs are inadvertently se-
lected as a result of passaging. To enhance clinical trans-
lation, careful characterization prior to transplantation is
necessary in order to isolate the population most benefi-
cial for the intended therapy and to ensure safety against
chromosomal instability.
Conclusions
In summary, our study provides additional evidence that
transplantation of BM MSCs holds significant promise
to delay the onset of motor, cognitive, and neuropatho-
logical loss in HD, most probably through the release of
neurotrophic factors, specifically BDNF. This study also
underscores the need to consider the passage number
when evaluating the efficacy of MSC transplantation
therapies.
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